Recent Comments

Comment RSS

Drug Trial News RSS Feed - Drug Trial News

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

19. November 2009 00:49
Viron Therapeutics Inc., a biotechnology company pioneering the development of immune-modulating protein therapeutics derived from pathogens, today reported results from a Phase IIa clinical trial evaluating VT-111 (Serp-1), an anti-inflammatory protein derived from the myxoma virus. [More]

Once-a-day dosing clinical study of udenafil for erectile dysfunction completed

19. November 2009 00:44
Dong-A Pharmaceutical Co., Ltd. and Dong-A PharmTech, Co. Ltd. announced today that it has completed a 240 patient once-a-day dosing clinical study of udenafil, its new long acting phosphodiesterase type 5 (PDE-5) inhibitor for erectile dysfunction (ED). [More]

Interim data from an ongoing phase 1 dose-escalation trial of XL147 reported

19. November 2009 00:22
Exelixis, Inc. today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors. [More]

Key findings from AstraZeneca's phase II studies of ticagrelor

18. November 2009 10:42
AstraZeneca today announced the results of the phase II studies, ONSET/OFFSET and RESPOND for ticagrelor (BRILINTA(TM)) at the annual American Heart Association (AHA) Scientific Sessions in Orlando, FL,with ONSET/OFFSET study results being simultaneously published in the medical journal Circulation. [More]

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

18. November 2009 10:31
Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company’s second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March. [More]

Lee's Pharmaceutical granted exclusive license to Jennerex' lead product for HCC

18. November 2009 09:34
Jennerex, Inc., a clinical-stage biotherapeutics company developing a proprietary breakthrough class of targeted oncolytic virus therapeutics, today announced in conjunction with Lee's Pharmaceutical Holdings, the execution of a collaboration and license agreement for Jennerex's lead product candidate, JX-594, in certain Asian territories. [More]

CytRx plans Phase 2 clinical trial of its doxorubicin prodrug for advanced gastric cancer

18. November 2009 09:14
CytRx Corporation, a biopharmaceutical company, today announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a second-line treatment in patients with advanced gastric (stomach) cancer. [More]

Epiphany Biosciences announces results from its valomaciclovir Phase 2b trial for shingles

18. November 2009 08:52
Epiphany Biosciences announced results from its Phase 2b dose-ranging study of EPB-348 (valomaciclovir) in patients with shingles (herpes zoster) infection. The study's primary endpoint was non-inferiority of once-daily valomaciclovir compared to thrice-daily valacyclovir in terms of time to complete crusting of the shingles rash. [More]

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

18. November 2009 08:40
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical data presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics shows that STA-9090, a novel, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated strong activity in multiple tumor models. [More]

Recent data from CNSBio's Phase IIa CNSB015 trial to be presented at the Neuropathic Pain conference

18. November 2009 08:24
CNSBio Inc. will present recent Phase IIa proof-of-concept clinical trial data for CNSB015, an orally administered potassium channel modulator used in combination with opioids for the treatment of neuropathic pain, at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain on November 20-21, 2009 in San Francisco, CA. [More]

Posted in: Drug Trial News | Medical Condition News

Tags: , , , ,

Clinical Data commences patient enrollment in Stedivaze Phase III trial

18. November 2009 08:13
Clinical Data, Inc. today announced that it has enrolled the first patient in its initial Phase III trial of Stedivaze™, a potential best-in-class vasodilator for use in cardiac stress testing. The study will evaluate the safety and efficacy of Stedivaze (apadenoson) for use as a pharmacologic stress agent in myocardial perfusion imaging (MPI), a method for detecting defects in the blood supply to the heart. [More]

New pre-clinical data from Alnylam Pharmaceuticals' ALN-VSP program presented

18. November 2009 07:38
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced new pre-clinical data from its ALN-VSP program presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International conference being held November 15 - 19, 2009 in Boston, Mass. [More]

Positive results from REVIVE, a phase 3 pivotal study of avanafil announced

18. November 2009 07:16
VIVUS, Inc. today announced positive results from REVIVE (TA-301), a phase 3 pivotal study evaluating the safety and efficacy of avanafil, an investigational drug candidate for the treatment of erectile dysfunction (ED), in 646 patients. [More]

Phase 2/3 study results of Genzyme's APB announced

18. November 2009 07:06
Genzyme Corporation today reported results of a phase 2/3 study of its advanced phosphate binder (APB). The trial met its primary endpoint, which was to show that the APB lowered phosphate levels effectively compared to placebo. However, the APB did not show a significant improvement in phosphate lowering compared to Genzyme’s Renvela® (sevelamer carbonate). [More]

Posted in: Drug Trial News | Medical Condition News

Tags: , , , ,

Pluristem’s PLX-PAD holds promise for critical limb ischemia

18. November 2009 06:21
Pluristem Therapeutics Inc. today announced that safety and potential efficacy parameters were demonstrated by the three month follow up data from the first patient ever to receive its placenta derived cell therapy product, PLX-PAD. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the company’s leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD). [More]

Posted in: Drug Trial News | Medical Condition News

Tags: , , ,

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.